New Treatment Offers Hope for Beating Aggressive Cancers

NASHVILLE, Tenn., April 29 /PRNewswire/ -- With an 89% initial success
rate in arresting or eradicating some of the most aggressive cancers, a
Nashville-based treatment is being offered to the public for the first time.
According to NeoPlas Innovation Director of Research Dr. Stephen Cantrell,
gathering more data to validate effectiveness is imperative, but "early human
results are quite exciting. This treatment has been effective for malignant
melanoma, as well as pancreatic and some of the other worst-prognosis
cancers."
The new protocol incorporates a unique combination of FDA-approved drugs
already known to be safe, each used by millions of people for other
applications. When administered alone, these drugs show some benefit against
cancer, but not enough to make a difference for most patients. The combination
of the medicines, however, allows lower, more tolerable dosages and provides
effectiveness not seen in previous single-drug studies.
The NeoPlas treatment shows benefit in several aggressive malignancies
because it disables certain abnormal cellular processes many of them share.
Based on experience and relevant lab research to date, staff members expect
the best results for melanoma, pancreatic cancer, colon cancer, renal (kidney)
cancer, mesothelioma, and a group of sarcomas, including osteosarcoma,
chondrosarcoma and malignant fibrous histiocytoma. Patients who have other
cancers can be considered on a case-by-case basis, since many of them may
benefit also. Having received previous cancer treatments does not make a
patient ineligible.
The regimen's most notable side-effect is fatigue. Most patients never
experience nausea, vomiting, hair loss, bone marrow or immune system
suppression, or other side-effects commonly affiliated with chemotherapy or
radiation. An experienced physician prescribes and monitors all treatment and
maintains close communication with the patient's established oncologist.
NeoPlas Innovation serves patients living throughout the country. Since
treatment takes place on an outpatient basis, most patients travel to
Nashville about once every two months. Additionally, physicians usually can
tell if the program is working within eight weeks and quickly enable patients
to make their best healthcare decisions.
NeoPlas Innovation's web site, www.neoplas.org , provides complete
information and an interactive screening tool for patients who are considering
this treatment. The center can be reached by calling 615-371-8100 or e-mailing
office@neoplas.org.
SOURCE NeoPlas Innovation

Dawn Bramblett, +1-731-989-8019, +1-731-608-7650, dawn@bramblettgrp.com, for
NeoPlas Innovation